CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it will host a live webcast to present and discuss the newly disclosed, late-breaking 48-week Phase 3 clinical data in China for...

People

6 Energy-Saving Tips

Facial Injectable Market Forecasts Report 2025-2030, Competitive Analysis of Key Players...

The Beauty Health Company Announces Convertible Debt Refinancing

ECD Auto Design Unleashes ‘67 Ghost — The First in a...

Bread Financial Announces Modified Dutch Auction Cash Tender Offer for 9.750%...

E-Commerce Warehouse Strategic Business Report 2025 | Warehouse-as-a-Service (WaaS) Platforms Enable...

U.S. Women’s Grooming Market Set to Reach $82.2 Billion by 2030:...

Allstar Coaches Rolls Into the Northeast with New State-of-the-Art Pennsylvania RV...

XWELL Reports First Quarter 2025 Results, Advancing Mission to Liberate Science-Proven...

Global Times: Chinese opera’s storytelling embeds philosophical depth in the core...

Kering: Bond issue for a total amount of EUR 750 million

Featured

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept...

6 Energy-Saving Tips

Saudia Unveils SV Lifestyle Brand at Riyadh Fashion Week

All Star Digital and Dart Co Launch One Hitters: Exclusive Partnership...

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept...